Literature DB >> 15078988

The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer.

Sangeeta Rojanala1, Haiyong Han, Rubén M Muñoz, Walden Browne, Raymond Nagle, Daniel D Von Hoff, David J Bearss.   

Abstract

Aurora-2 is a serine threonine kinase that associates with the centrosome. Overexpression or ectopic expression of Aurora-2 appears to alter centrosome number and function and has been implicated in a variety of human cancers. In this work, we demonstrate that Aurora-2 is both amplified and overexpressed in human pancreatic cancer cell lines, with a 2-5-fold increase in gene copy number and a 3-4-fold increase in protein levels compared with controls. Aurora-2 is also amplified and overexpressed in pancreatic cancers taken directly from patients. An immunohistochemistry of tissues taken directly from patients demonstrated an overexpression of Aurora-2 in 26 of 28 pancreatic cancers compared with 18 normal pancreas samples. Antisense nucleotides specifically targeted at Aurora-2 arrest the cell cycle in pancreatic cancer cells, indicating the potential of Aurora-2 as a therapeutic target in pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15078988

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  23 in total

1.  The induction of polyploidy or apoptosis by the Aurora A kinase inhibitor MK8745 is p53-dependent.

Authors:  Jayasree S Nair; Alan L Ho; Gary K Schwartz
Journal:  Cell Cycle       Date:  2012-02-15       Impact factor: 4.534

2.  Mass balance, routes of excretion, and pharmacokinetics of investigational oral [14C]-alisertib (MLN8237), an Aurora A kinase inhibitor in patients with advanced solid tumors.

Authors:  Xiaofei Zhou; Sandeepraj Pusalkar; Swapan K Chowdhury; Shawn Searle; Yuexian Li; Claudio Dansky Ullmann; Karthik Venkatakrishnan
Journal:  Invest New Drugs       Date:  2018-11-06       Impact factor: 3.850

Review 3.  Tubulin-associated proteins: Aurora and Polo-like kinases as therapeutic targets in cancer.

Authors:  Steven L Warner; Bret J Stephens; Daniel D Von Hoff
Journal:  Curr Oncol Rep       Date:  2008-03       Impact factor: 5.075

4.  The molecular mechanism studies of chirality effect of PHA-739358 on Aurora kinase A by molecular dynamics simulation and free energy calculations.

Authors:  Yuanhua Cheng; Wei Cui; Quan Chen; Chen-Ho Tung; Mingjuan Ji; Fushi Zhang
Journal:  J Comput Aided Mol Des       Date:  2011-01-11       Impact factor: 3.686

5.  Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer.

Authors:  Laura W Goff; Nilofer S Azad; Stacey Stein; Jennifer G Whisenant; Tatsuki Koyama; Ulka Vaishampayan; Howard Hochster; Roisin Connolly; Amy Weise; Patricia M LoRusso; Safia N Salaria; Wael El-Rifai; Jordan D Berlin
Journal:  Invest New Drugs       Date:  2018-09-06       Impact factor: 3.850

6.  Kinome-wide siRNA screening identifies molecular targets mediating the sensitivity of pancreatic cancer cells to Aurora kinase inhibitors.

Authors:  Lifang Xie; Michelle Kassner; Ruben M Munoz; Qiang Q Que; Jeff Kiefer; Yu Zhao; Spyro Mousses; Hongwei H Yin; Daniel D Von Hoff; Haiyong Han
Journal:  Biochem Pharmacol       Date:  2011-11-15       Impact factor: 5.858

7.  Copy-number increase of AURKA in gastric cancers in a Chinese population: a correlation with tumor progression.

Authors:  Zhengyu Fang; Yi Xiong; Jiana Li; Li Liu; Manhui Li; Chao Zhang; Wei Zhang; Jun Wan
Journal:  Med Oncol       Date:  2010-06-29       Impact factor: 3.064

8.  Pdx-1-driven overexpression of aurora a kinase induces mild ductal dysplasia of pancreatic ducts near islets in transgenic mice.

Authors:  Steven L Warner; Ruben M Muñoz; David J Bearss; Paul Grippo; Haiyong Han; Daniel D Von Hoff
Journal:  Pancreas       Date:  2008-10       Impact factor: 3.327

9.  Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen.

Authors:  John McLaughlin; Vadim Markovtsov; Hui Li; Steve Wong; Marina Gelman; Yanhong Zhu; Christian Franci; D Wayne Lang; Erlina Pali; Joe Lasaga; Caroline Low; Feifei Zhao; Betty Chang; Tarikere L Gururaja; Weiduan Xu; Muhammad Baluom; David Sweeny; David Carroll; Arvinder Sran; Sambaiah Thota; Manjeet Parmer; Angela Romane; George Clemens; Elliott Grossbard; Kunbin Qu; Yonchu Jenkins; Taisei Kinoshita; Vanessa Taylor; Sacha J Holland; Ankush Argade; Rajinder Singh; Polly Pine; Donald G Payan; Yasumichi Hitoshi
Journal:  J Cancer Res Clin Oncol       Date:  2010-01       Impact factor: 4.553

10.  Aurora kinase A inhibition and paclitaxel as targeted combination therapy for head and neck squamous cell carcinoma.

Authors:  Abhijit Mazumdar; Ying C Henderson; Adel K El-Naggar; Subrata Sen; Gary L Clayman
Journal:  Head Neck       Date:  2009-05       Impact factor: 3.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.